S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Japan firm opens whale meat vending machines to push sales
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:SRZN

Surrozen - SRZN Stock Forecast, Price & News

$0.72
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.72
▼
$0.79
50-Day Range
$0.42
▼
$0.89
52-Week Range
$0.34
▼
$3.97
Volume
409,438 shs
Average Volume
753,427 shs
Market Capitalization
$25.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Surrozen MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.43mentions of Surrozen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.46) to ($1.18) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

308th out of 1,055 stocks

Biological Products, Except Diagnostic Industry

53rd out of 170 stocks

See Top Rated MarketRank™ Stocks Here

SRZN stock logo

About Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

SRZN Stock News Headlines

January 4, 2023 | finance.yahoo.com
Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 2, 2023 | finance.yahoo.com
Surrozen, Inc. (SRZN) Stock Historical Prices & Data - Yahoo Finance
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
December 30, 2022 | finance.yahoo.com
Surrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should Know
December 15, 2022 | benzinga.com
How Is The Market Feeling About Surrozen?
November 29, 2022 | benzinga.com
JP Morgan Downgrades Surrozen to Underweight
November 16, 2022 | finance.yahoo.com
Surrozen Pauses Early-Stage Ulcerative Colitis Study Due To Liver Associated Adverse Events
November 16, 2022 | msn.com
Peering Into Surrozen's Recent Short Interest
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
November 15, 2022 | finance.yahoo.com
Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 10, 2022 | finance.yahoo.com
Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week
October 6, 2022 | finance.yahoo.com
Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate
October 4, 2022 | uk.finance.yahoo.com
Surrozen, Inc. (SRZN)
September 26, 2022 | finance.yahoo.com
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
August 11, 2022 | finance.yahoo.com
Surrozen Reports Second Quarter 2022 Financial Results
June 27, 2022 | finance.yahoo.com
What Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)?
June 13, 2022 | finance.yahoo.com
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
May 24, 2022 | finance.yahoo.com
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
May 18, 2022 | msn.com
Surrozen Commences Phase 1 Study of SZN-1326 In Ulcerative Colitis
May 18, 2022 | finance.yahoo.com
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
May 16, 2022 | finance.yahoo.com
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)
May 11, 2022 | finance.yahoo.com
Surrozen Reports First Quarter 2022 Financial Results
May 5, 2022 | finance.yahoo.com
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
May 2, 2022 | finance.yahoo.com
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
March 24, 2022 | finance.yahoo.com
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
March 10, 2022 | seekingalpha.com
CPSH and SRZN among mid-day movers
January 14, 2022 | nasdaq.com
Surrozen Inc Shares Near 52-Week Low - Market Mover
See More Headlines
Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

SRZN Company Calendar

Last Earnings
11/14/2022
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRZN
CUSIP
N/A
CIK
1824893
Web
www.consonancehfw.com
Phone
650-489-9000
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-54,650,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-52.89%
Return on Assets
-44.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.56
Quick Ratio
9.56

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.13 per share
Price / Book
0.23

Miscellaneous

Outstanding Shares
35,120,000
Free Float
24,797,000
Market Cap
$25.29 million
Optionable
Not Optionable
Beta
-0.24

Key Executives

  • Mr. Craig C. Parker M.B.A. (Age 61)
    CEO, Pres & Director
    Comp: $741.9k
  • Mr. Charles Williams (Age 43)
    Chief Financial Officer
    Comp: $530.91k
  • Dr. Wen-Chen Yeh M.D. (Age 59)
    Ph.D., Chief Scientific Officer
    Comp: $528.03k
  • Dr. K. Christopher Garcia Ph.D.
    Co-Founder & Member of Scientific Advisor
  • Dr. Roeland Nusse Ph.D. (Age 73)
    Co-Founder & Member of Scientific Advisor
  • Dr. Calvin Kuo M.D.
    Ph.D., Co-Founder & Member of Scientific Advisor
  • Ms. Sheela Mohan-Peterson J.D. (Age 61)
    M.S., Sr. VP of Legal, Gen. Counsel & Corp. Sec.
  • Dr. Geertrui Vanhove M.B.A. (Age 57)
    M.D., Ph.D., Chief Medical Officer
  • Dr. Li Yang Ph.D.
    Sr. VP of Biology
  • Ms. Elizabeth Nguyen
    Sr. VP and Head of Talent & Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













SRZN Stock - Frequently Asked Questions

Should I buy or sell Surrozen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surrozen in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" SRZN shares.
View SRZN analyst ratings or view top-rated stocks.

How have SRZN shares performed in 2023?

Surrozen's stock was trading at $0.5819 at the start of the year. Since then, SRZN stock has increased by 23.7% and is now trading at $0.72.
View the best growth stocks for 2023 here.

Are investors shorting Surrozen?

Surrozen saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 227,300 shares, a drop of 18.7% from the December 31st total of 279,700 shares. Based on an average trading volume of 812,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.2% of the shares of the company are sold short.
View Surrozen's Short Interest.

When is Surrozen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our SRZN earnings forecast.

How were Surrozen's earnings last quarter?

Surrozen, Inc. (NASDAQ:SRZN) released its earnings results on Monday, November, 14th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05.

What is Surrozen's stock symbol?

Surrozen trades on the NASDAQ under the ticker symbol "SRZN."

How do I buy shares of Surrozen?

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Surrozen's stock price today?

One share of SRZN stock can currently be purchased for approximately $0.72.

How much money does Surrozen make?

Surrozen (NASDAQ:SRZN) has a market capitalization of $25.29 million. The company earns $-54,650,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

How can I contact Surrozen?

Surrozen's mailing address is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. The official website for the company is www.consonancehfw.com. The company can be reached via phone at 650-489-9000 or via email at chfw-info@consonancelifesciences.com.

This page (NASDAQ:SRZN) was last updated on 1/28/2023 by MarketBeat.com Staff